Today, we face a critical gap. Pharmaceutical companies often prioritize profitable chronic condition drugs over one-time-use antibiotics, leading to a cessation of research into new bacterial combatants.
E. To combat this, global health leaders are calling for a "One Health" approach. This strategy recognizes that human health is closely connected to the health of animals and the environment. Interventions include stricter regulations on prescriptions, the development of new diagnostic tools to ensure antibiotics are only used when necessary, and significant investment in the research and development of new antibiotics. However, the pipeline for new drugs is drying up because antibiotics are less profitable for pharmaceutical companies than drugs for chronic conditions. Consequently, governments must provide financial incentives to encourage innovation. Today, we face a critical gap
: Newer antibiotics can cost between £1,000 to £3,000 per course, making them significantly more expensive than older, less effective ones. To combat this, global health leaders are calling